Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 514 participants.

Also called NCT05691244

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 514 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05691244
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Germany, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05691244. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-24 (actual); primary completion 2027-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Acronym
RESPECT-ETB
Condition
Acute Ischemic Stroke
Condition
Cerebral Stroke
Intervention (Drug)
Drug: Normal Saline
Intervention (Drug)
Sovateltide
Lead sponsor
Pharmazz, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05691244
Content hash
88bee31a935a8b448e9ae1a8c9aaf36107bc36e2b2a0e131ee8954534f517407